liquid chromatography tandem mass spectrometry assay  (Celerion)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Celerion liquid chromatography tandem mass spectrometry assay
    Liquid Chromatography Tandem Mass Spectrometry Assay, supplied by Celerion, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/liquid chromatography tandem mass spectrometry assay/product/Celerion
    Average 92 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    liquid chromatography tandem mass spectrometry assay - by Bioz Stars, 2020-07
    92/100 stars

    Images

    Related Articles

    Chromatography:

    Article Title: Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes
    Article Snippet: .. Semaglutide plasma concentrations were measured using a validated liquid chromatography‐tandem mass spectrometry assay (Celerion Inc., Fehraltorf, Switzerland), as previously described. ..

    Mass Spectrometry:

    Article Title: Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes
    Article Snippet: .. Semaglutide plasma concentrations were measured using a validated liquid chromatography‐tandem mass spectrometry assay (Celerion Inc., Fehraltorf, Switzerland), as previously described. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Celerion laboratory assessments semaglutide concentrations
    Plasma <t>semaglutide</t> concentration–time profiles in participants with normal hepatic function and those with hepatic impairment after a single dose of subcutaneous semaglutide 0.5 mg. A, Geometric mean profiles. B–E, Individual participant profiles. The circled data point in E represents the outlier excluded from the sensitivity analysis for C max . Data are geometric means. Values below the lower limit of quantification (represented by the dotted line) were imputed
    Laboratory Assessments Semaglutide Concentrations, supplied by Celerion, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/laboratory assessments semaglutide concentrations/product/Celerion
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    laboratory assessments semaglutide concentrations - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    93
    Celerion pharmacokinetics edasalonexent
    Mean Plasma Concentrations versus Time and Plasma <t>Edasalonexent</t> AUC. A. Mean edasalonexent plasma concentrations Day 1 and Day 7 following single edasalonexent doses of 17 (squares), 33 (triangles) or 67 (circles) mg/kg. B. Mean salicyluric acid plasma concentrations Day 1 and Day 7 following single edasalonexent doses of 17 (squares), 33 (triangles) or 67 (circles) mg/kg. C. Pooled Day 1 and Day 7 AUC and Cmax after single daily doses of edasalonexent at 17, 33 and 67 mg/kg administered with low-fat and high-fat meals.
    Pharmacokinetics Edasalonexent, supplied by Celerion, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pharmacokinetics edasalonexent/product/Celerion
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pharmacokinetics edasalonexent - by Bioz Stars, 2020-07
    93/100 stars
      Buy from Supplier

    92
    Celerion semaglutide plasma concentrations
    Simulated <t>semaglutide</t> concentration profiles following missed or delayed doses. Data are simulated concentrations during once-weekly dosing at steady-state concentrations with one missed dose at week 11 ( a ) and for a dose with a delay of 5 days at week 11 ( b ) compared with a steady-state profile for semaglutide dosed at weekly intervals. Simulations are for a reference subject profile (non-Hispanic or Latino, white female
    Semaglutide Plasma Concentrations, supplied by Celerion, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/semaglutide plasma concentrations/product/Celerion
    Average 92 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    semaglutide plasma concentrations - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    90
    Celerion sumatriptan
    <t>Sumatriptan</t> plasma concentration-time profiles over the entire 14-hour sampling period for intranasal sumatriptan powder, 22-mg nasal spray, 100-mg tablet, and 6-mg subcutaneous injection and Inset for intranasal sumatriptan powder, 22-mg nasal spray, and 100-mg tablet over the first 30 minutes post-dose. The main figure shows that both methods of intranasal delivery resulted in much lower mean plasma sumatriptan concentration time profiles than observed for the tablet and the injection. Inset: In the first 15 minutes post-dose, the rate of rise of plasma sumatriptan concentration was faster for sumatriptan powder than either the 20-mg nasal spray or the 100-mg tablet.
    Sumatriptan, supplied by Celerion, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sumatriptan/product/Celerion
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sumatriptan - by Bioz Stars, 2020-07
    90/100 stars
      Buy from Supplier

    Image Search Results


    Plasma semaglutide concentration–time profiles in participants with normal hepatic function and those with hepatic impairment after a single dose of subcutaneous semaglutide 0.5 mg. A, Geometric mean profiles. B–E, Individual participant profiles. The circled data point in E represents the outlier excluded from the sensitivity analysis for C max . Data are geometric means. Values below the lower limit of quantification (represented by the dotted line) were imputed

    Journal: Diabetes, Obesity & Metabolism

    Article Title: Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment

    doi: 10.1111/dom.13186

    Figure Lengend Snippet: Plasma semaglutide concentration–time profiles in participants with normal hepatic function and those with hepatic impairment after a single dose of subcutaneous semaglutide 0.5 mg. A, Geometric mean profiles. B–E, Individual participant profiles. The circled data point in E represents the outlier excluded from the sensitivity analysis for C max . Data are geometric means. Values below the lower limit of quantification (represented by the dotted line) were imputed

    Article Snippet: 2.4 Laboratory assessments Semaglutide concentrations in plasma were analysed using liquid chromatography with tandem mass spectrometry (LC‐MS/MS; Celerion Inc., Fehraltorf, Switzerland), as previously reported.

    Techniques: Concentration Assay

    Mean Plasma Concentrations versus Time and Plasma Edasalonexent AUC. A. Mean edasalonexent plasma concentrations Day 1 and Day 7 following single edasalonexent doses of 17 (squares), 33 (triangles) or 67 (circles) mg/kg. B. Mean salicyluric acid plasma concentrations Day 1 and Day 7 following single edasalonexent doses of 17 (squares), 33 (triangles) or 67 (circles) mg/kg. C. Pooled Day 1 and Day 7 AUC and Cmax after single daily doses of edasalonexent at 17, 33 and 67 mg/kg administered with low-fat and high-fat meals.

    Journal: Journal of Neuromuscular Diseases

    Article Title: Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy

    doi: 10.3233/JND-180341

    Figure Lengend Snippet: Mean Plasma Concentrations versus Time and Plasma Edasalonexent AUC. A. Mean edasalonexent plasma concentrations Day 1 and Day 7 following single edasalonexent doses of 17 (squares), 33 (triangles) or 67 (circles) mg/kg. B. Mean salicyluric acid plasma concentrations Day 1 and Day 7 following single edasalonexent doses of 17 (squares), 33 (triangles) or 67 (circles) mg/kg. C. Pooled Day 1 and Day 7 AUC and Cmax after single daily doses of edasalonexent at 17, 33 and 67 mg/kg administered with low-fat and high-fat meals.

    Article Snippet: Pharmacokinetics Edasalonexent, salicyluric acid, linker-salicylic acid, linker-DHA and salicylic acid in blood and salicylic acid, linker-salicylic acid, and salicyluric acid were determined using validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) methods at Celerion (Lincoln, NE).

    Techniques:

    Effect of Edasalonexent on NF- κ B: Change in Expression of NF- κ B-Target Genes Following Edasalonexent Treatment. Whole blood mRNA was isolated at baseline and after 1 week of edasalonexent administration. Gene expression was measured in gene sets with (unshaded area) and without (shaded area) enrichment for NF- κ B-regulated genes.

    Journal: Journal of Neuromuscular Diseases

    Article Title: Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy

    doi: 10.3233/JND-180341

    Figure Lengend Snippet: Effect of Edasalonexent on NF- κ B: Change in Expression of NF- κ B-Target Genes Following Edasalonexent Treatment. Whole blood mRNA was isolated at baseline and after 1 week of edasalonexent administration. Gene expression was measured in gene sets with (unshaded area) and without (shaded area) enrichment for NF- κ B-regulated genes.

    Article Snippet: Pharmacokinetics Edasalonexent, salicyluric acid, linker-salicylic acid, linker-DHA and salicylic acid in blood and salicylic acid, linker-salicylic acid, and salicyluric acid were determined using validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) methods at Celerion (Lincoln, NE).

    Techniques: Expressing, Isolation

    Simulated semaglutide concentration profiles following missed or delayed doses. Data are simulated concentrations during once-weekly dosing at steady-state concentrations with one missed dose at week 11 ( a ) and for a dose with a delay of 5 days at week 11 ( b ) compared with a steady-state profile for semaglutide dosed at weekly intervals. Simulations are for a reference subject profile (non-Hispanic or Latino, white female

    Journal: Diabetes Therapy

    Article Title: Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

    doi: 10.1007/s13300-018-0458-5

    Figure Lengend Snippet: Simulated semaglutide concentration profiles following missed or delayed doses. Data are simulated concentrations during once-weekly dosing at steady-state concentrations with one missed dose at week 11 ( a ) and for a dose with a delay of 5 days at week 11 ( b ) compared with a steady-state profile for semaglutide dosed at weekly intervals. Simulations are for a reference subject profile (non-Hispanic or Latino, white female

    Article Snippet: The semaglutide plasma concentrations were measured following protein precipitation using a validated liquid chromatography assay followed by a tandem mass spectrometry assay (Celerion Inc. Fehraltorf, Switzerland); see [ ] for more details.

    Techniques: Concentration Assay

    Distribution of exposure values from trials included in the population PK analysis. a Exposure for subjects treated with 0.5 mg semaglutide; b exposure for subjects treated with 1.0 mg semaglutide. PK pharmacokinetic, SUSTAIN Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes

    Journal: Diabetes Therapy

    Article Title: Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

    doi: 10.1007/s13300-018-0458-5

    Figure Lengend Snippet: Distribution of exposure values from trials included in the population PK analysis. a Exposure for subjects treated with 0.5 mg semaglutide; b exposure for subjects treated with 1.0 mg semaglutide. PK pharmacokinetic, SUSTAIN Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes

    Article Snippet: The semaglutide plasma concentrations were measured following protein precipitation using a validated liquid chromatography assay followed by a tandem mass spectrometry assay (Celerion Inc. Fehraltorf, Switzerland); see [ ] for more details.

    Techniques:

    Forest plot of covariate analysis for semaglutide exposure expressed as steady-state dose-normalized average semaglutide concentrations relative to a reference subject. The reference subject profile was non-Hispanic or Latino, white, female, below 65 years, with a body weight of 85 kg, with normal renal function, and who was dosed in the abdomen with semaglutide 1 mg. The column to the right shows means and 90% CI for the relative exposures. Two additional race groups (American Indian or Alaska native, n = 3 subjects, and unknown, n = 41) were included in the analysis without a separate race covariate, i.e., modeled as the reference race group (white) in the covariate analysis. Subjects without information on race were from France ( n = 20), Mexico ( n = 13), Canada and the USA ( n = 2 each), Australia, Norway, South Africa, and the UK ( n = 1 each). Body weight test categories (55 and 127 kg) represent the 5% and 95% percentiles, respectively, in the data set. Vertical dotted lines indicate the acceptance interval for bioequivalence (0.80; 1.25). C avg average semaglutide concentrations at steady state; CI confidence interval

    Journal: Diabetes Therapy

    Article Title: Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

    doi: 10.1007/s13300-018-0458-5

    Figure Lengend Snippet: Forest plot of covariate analysis for semaglutide exposure expressed as steady-state dose-normalized average semaglutide concentrations relative to a reference subject. The reference subject profile was non-Hispanic or Latino, white, female, below 65 years, with a body weight of 85 kg, with normal renal function, and who was dosed in the abdomen with semaglutide 1 mg. The column to the right shows means and 90% CI for the relative exposures. Two additional race groups (American Indian or Alaska native, n = 3 subjects, and unknown, n = 41) were included in the analysis without a separate race covariate, i.e., modeled as the reference race group (white) in the covariate analysis. Subjects without information on race were from France ( n = 20), Mexico ( n = 13), Canada and the USA ( n = 2 each), Australia, Norway, South Africa, and the UK ( n = 1 each). Body weight test categories (55 and 127 kg) represent the 5% and 95% percentiles, respectively, in the data set. Vertical dotted lines indicate the acceptance interval for bioequivalence (0.80; 1.25). C avg average semaglutide concentrations at steady state; CI confidence interval

    Article Snippet: The semaglutide plasma concentrations were measured following protein precipitation using a validated liquid chromatography assay followed by a tandem mass spectrometry assay (Celerion Inc. Fehraltorf, Switzerland); see [ ] for more details.

    Techniques:

    Semaglutide exposure versus body weight. Data are dose-normalized individual average semaglutide concentrations ( C avg ) versus baseline body weight (small rectangles) and mean exposure estimates versus body weight presented in 10 quantiles by sex ( a ) or by ethnicity ( b )

    Journal: Diabetes Therapy

    Article Title: Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

    doi: 10.1007/s13300-018-0458-5

    Figure Lengend Snippet: Semaglutide exposure versus body weight. Data are dose-normalized individual average semaglutide concentrations ( C avg ) versus baseline body weight (small rectangles) and mean exposure estimates versus body weight presented in 10 quantiles by sex ( a ) or by ethnicity ( b )

    Article Snippet: The semaglutide plasma concentrations were measured following protein precipitation using a validated liquid chromatography assay followed by a tandem mass spectrometry assay (Celerion Inc. Fehraltorf, Switzerland); see [ ] for more details.

    Techniques:

    Simulated concentration profiles for semaglutide 0.5 mg ( a ) or 1.0 mg ( b ) at steady state over 3 weeks, with variability. The shaded area illustrates the simulated 95% concentration range predicted from the between-subject variability in the full population PK model ( N = 1000 replications in each group). BW body weight

    Journal: Diabetes Therapy

    Article Title: Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

    doi: 10.1007/s13300-018-0458-5

    Figure Lengend Snippet: Simulated concentration profiles for semaglutide 0.5 mg ( a ) or 1.0 mg ( b ) at steady state over 3 weeks, with variability. The shaded area illustrates the simulated 95% concentration range predicted from the between-subject variability in the full population PK model ( N = 1000 replications in each group). BW body weight

    Article Snippet: The semaglutide plasma concentrations were measured following protein precipitation using a validated liquid chromatography assay followed by a tandem mass spectrometry assay (Celerion Inc. Fehraltorf, Switzerland); see [ ] for more details.

    Techniques: Concentration Assay

    Sumatriptan plasma concentration-time profiles over the entire 14-hour sampling period for intranasal sumatriptan powder, 22-mg nasal spray, 100-mg tablet, and 6-mg subcutaneous injection and Inset for intranasal sumatriptan powder, 22-mg nasal spray, and 100-mg tablet over the first 30 minutes post-dose. The main figure shows that both methods of intranasal delivery resulted in much lower mean plasma sumatriptan concentration time profiles than observed for the tablet and the injection. Inset: In the first 15 minutes post-dose, the rate of rise of plasma sumatriptan concentration was faster for sumatriptan powder than either the 20-mg nasal spray or the 100-mg tablet.

    Journal: Headache

    Article Title: Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder

    doi: 10.1111/head.12167

    Figure Lengend Snippet: Sumatriptan plasma concentration-time profiles over the entire 14-hour sampling period for intranasal sumatriptan powder, 22-mg nasal spray, 100-mg tablet, and 6-mg subcutaneous injection and Inset for intranasal sumatriptan powder, 22-mg nasal spray, and 100-mg tablet over the first 30 minutes post-dose. The main figure shows that both methods of intranasal delivery resulted in much lower mean plasma sumatriptan concentration time profiles than observed for the tablet and the injection. Inset: In the first 15 minutes post-dose, the rate of rise of plasma sumatriptan concentration was faster for sumatriptan powder than either the 20-mg nasal spray or the 100-mg tablet.

    Article Snippet: Plasma samples were analyzed for sumatriptan at the Celerion Bioanalysis Laboratory in Lincoln, NE, USA, using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.

    Techniques: Concentration Assay, Sampling, Injection

    Sumatriptan plasma concentration time profiles over the first 4 hours after administration of 22-mg sumatriptan powder by the Breath Powered device compared with the 20-mg nasal spray.

    Journal: Headache

    Article Title: Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder

    doi: 10.1111/head.12167

    Figure Lengend Snippet: Sumatriptan plasma concentration time profiles over the first 4 hours after administration of 22-mg sumatriptan powder by the Breath Powered device compared with the 20-mg nasal spray.

    Article Snippet: Plasma samples were analyzed for sumatriptan at the Celerion Bioanalysis Laboratory in Lincoln, NE, USA, using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.

    Techniques: Concentration Assay